Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up.

Mikhael F El-ChamiLindsay BockstedtColleen LongacreLucas HigueraKurt StrombergGeorge CrossleyRobert C KowalJonathan P Piccini

Published in: European heart journal (2021)

In a real-world study of US Medicare patients, the Micra leadless VVI pacemaker was associated with a 38% lower adjusted rate of reinterventions and a 31% lower adjusted rate of chronic complications compared with transvenous VVI pacing. There was no difference in adjusted all-cause mortality at 2 years.

Keyphrases

heart failure
end stage renal disease
newly diagnosed
ejection fraction
cardiac resynchronization therapy
atrial fibrillation
patient reported
drug induced